[MOL] Phase 11 Study SCLC info..... [00273] Medicine On Line

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] Phase 11 Study SCLC info.....

Title: Phase II Study of Area Under the
  Plasma-Concentration-Versus-Time Curve–Based
  Carboplatin Plus Standard-Dose Intravenous Etoposide in
  Elderly Patients With Small-Cell Lung Cancer
Abstract: The median survival time was 10.8 months (LD,
  11.6 months; ED, 10.1 months), and the 1-year survival
  rate was 47%. CONCLUSION: This carboplatin/etoposide
  combination chemotherapy is an active and relatively
  nontoxic regimen in elderly patients with SCLC, which
  suggests that the combination may be suitable for
  randomized controlled trials. INTRODUCTION TOP ABSTRACT
Source: Journal of Clinical Oncology